AstraZeneca
The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.
Inclusion Criteria: * Participant must be ≥ 18 years of age * Participants must be on a stable dose of all background LLTs * The stable statin dose should be judged as their maximally tolerated dose * Participants should have either history of a clinical ASCVD event or be at increased risk for a first clinical ASCVD event Exclusion Criteria: * Asian origin * Uncontrolled severe hypertension * Uncontrolled T2DM * Inadequately treated hypothyroidism
daily oral dose of the laroprovstat/rosuvastatin 1
daily oral dose of the laroprovstat/rosuvastatin 2
daily oral dose of the laroprovstat/rosuvastatin 3
daily oral dose of the laroprovstat/rosuvastatin 4
Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 1,2,3
Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 4
daily oral dose of rosuvastatin 1
daily oral dose of rosuvastatin 2
daily oral dose of rosuvastatin 3
daily oral dose of rosuvastatin 4
daily oral dose of placebo to match rosuvastatin